English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/156233
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

ASS234, as a new multi-target directed propargylamine for Alzheimer's disease therapy

AuthorsMarco-Contelles, José ; Unzeta, M.; Bolea, Irene; Esteban, G.; Ramsay, Rona R.; Romero, A. ; Martínez-Murillo, Ricardo ; Carreiras, M. Carmo; Ismaili, L.
Keywordsmonoamine oxidases
drugs
cholinesterases
Alzheimer's disease
multi-target directed ligands
Issue Date2016
CitationFrontiers in Neuromorphic Engineering 10 (2016)
AbstractThe complex nature of Alzheimer's disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL) able to bind to diverse biochemical targets involved in the progress and development of the disease. In this context, we have designed a number of MTD propargylamines (MTDP) showing antioxidant, anti-beta-amyloid, anti-inflammatory, as well as cholinesterase and monoamine oxidase (MAO) inhibition capacities. Here, we describe these properties in the MTDL ASS234, our lead-compound ready to enter in pre-clinical studies for AD, as a new multipotent, permeable cholinesterase/monoamine oxidase inhibitor, able to inhibit Aß-aggregation, and possessing antioxidant and neuroprotective properties.
URIhttp://hdl.handle.net/10261/156233
DOI10.3389/fnins.2016.00294
Identifiersdoi: 10.3389/fnins.2016.00294
issn: 1662-453X
Appears in Collections:(IC) Artículos
Files in This Item:
File Description SizeFormat 
Frontiers in Neuroscience.pdf418,62 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.